Symbolbild · KI-generiert
Kyverna Therapeutics, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Kyverna Therapeutics is a biotechnology company developing CAR-T cell therapies for autoimmune diseases. The company applies the CAR-T technology approach, originally developed for cancer, to difficult-to-treat autoimmune conditions such as lupus and multiple sclerosis. The company is in the clinical development stage.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Kyverna Therapeutics, Inc. | KYTX | NASDAQ | 444 Mio. USD |
| kneat.com inc. | KSI | TSX | 446 Mio. USD |
| Viemed Healthcare, Inc. | VMD | NASDAQ | 447 Mio. USD |
| ClearPoint Neuro, Inc. | CLPT | NASDAQ | 448 Mio. USD |
| Neuropace, Inc. | NPCE | NASDAQ | 439 Mio. USD |
| K-Bro Linen Inc. | KBL | TSX | 439 Mio. USD |
| Sagimet Biosciences Inc. Series A | SGMT | NASDAQ | 439 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.